A recent study published in Nature Biotechnology suggests that a drug called rentosertib, developed using artificial intelligence, may help reduce biological age. Initially designed to treat idiopathic pulmonary fibrosis (IPF), a severe lung condition that causes scarring and worsens over time, the drug was tested on 71 people with IPF. IPF primarily affects older adults, and its effects on the body—like inflammation and impaired tissue repair—are similar to those seen in aging. Researchers analyzed blood samples from 42 participants, looking at nearly 3,000 proteins that can signal biological changes linked to aging, inflammation, and tissue damage. They used six AI-based models, known as "biological clocks," to estimate each person's biological age. These models evaluated how the drug affected the participants over time. Those taking rentosertib showed a reduction in their biological age by up to 3.46 years, according to some of the models, while the placebo group either showed no change or even an increase in biological age. The most noticeable effects were seen after four weeks of treatment, particularly in those taking 60 mg of the drug daily. However, the researchers were unable to determine a single, consistent measure of the drug's overall impact on biological age. Rentosertib also altered the levels of 326 proteins compared to just two in the placebo group. These proteins are involved in lung healing, inflammation, cellular stress, and the function of aging or damaged cells. These changes were sustained throughout the 12-week study, but the biological rejuvenation effects plateaued after the fourth week, and the reason for this is unclear. The researchers suggest that the drug's positive impact on lung symptoms might be the reason for the observed biological rejuvenation in blood samples. It’s possible that the AI models detected improvements in the disease rather than a direct reversal of aging. The study was limited to 42 people with IPF, all followed for only 12 weeks, so it cannot be generalized to the broader population. Long-term health benefits or effects on lifespan remain unproven. The study was conducted by researchers affiliated with Insilico Medicine, the company behind rentosertib, and its lead author, Alex Zhavoronkov, is the founder and co-CEO of the company. While the findings are intriguing, the study does not currently support classifying rentosertib as an anti-aging drug. Larger, long-term studies are needed to validate these results and determine if the drug could have similar effects on people without IPF.